AstraZeneca ZD6474 preliminary Phase II data

AstraZeneca (LSE:AZN; AZN) said a preliminary analysis of a Phase II trial (Trial 006) to treat non-small cell lung cancer (NSCLC) showed that ZD6474 plus Taxotere docetaxel met the primary endpoint o...